$TEM · Tempus AI, Inc.
Tempus AI reported Q3 FY2026 results with revenue of $411.5M (+23% YoY), driven by 32% oncology volume growth and 33% Data & Applications growth. Adjusted EBITDA swung to $25.6M from $1.5M a year ago, while GAAP net loss narrowed to $(14.9)M from $(80.0)M. The company raised FY2026 revenue guidance to $1.60–$1.605B and reaffirmed ~$65M in Adjusted EBITDA.
- Total revenue of $411.5M, up 23% YoY, with Diagnostics at $303.5M (+20%) and Data & Applications at $108.1M (+33%).
- Oncology volume growth accelerated to 32%; MRD test volume surged ~300% to ~12,000 tests.
- Adjusted EBITDA swung to $25.6M from $1.5M in Q3 2025; net loss narrowed to $(14.9)M from $(80.0)M.
- Full-year 2026 revenue guidance raised to $1.60–$1.605B (~25% annual growth); Adjusted EBITDA expected at ~$65M.
- Cash and marketable securities of $854.4M; total data licensing bookings exceed $550M year to date.
Extended-hours trading shows TEM at $74.92, up +3.74% vs the regular-session close of $72.22, indicating a positive initial reaction to the revenue beat and raised guidance. The regular session had closed down 7.22% before the release; the after-hours pop suggests the market is rewarding the accelerating oncology volume and swing to positive Adjusted EBITDA.
Tempus is demonstrating a rare combination in health-tech AI: accelerating 32% oncology volume growth alongside a swing to profitability on an Adjusted EBITDA basis, while locking in >$550M in pharma data licensing deals.
Tempus is leveraging its diagnostic platform to cross-sell into high-value data licensing deals with pharma giants (Merck, Moderna, BMS), a model that differentiates it from pure-play diagnostics or AI-biotech peers. The >$550M in YTD data licensing bookings underscores the commercial traction of this strategy.
Pending Personalis acquisition (shareholder vote November 30, 2026) introduces integration risk. Hereditary revenue growth of just 3% lags significantly behind oncology's 32%, signaling potential weakness in that segment.